HENAN TALOPH PHARMACEUTICAL STOCK CO.,LTD |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.01 CNY | -0.79% |
|
+4.59% | -18.27% |
| Sales 2022 | 1.96B 271M | Sales 2023 | 2.07B 286M | Capitalization | 3.43B 473M |
|---|---|---|---|---|---|
| Net income 2022 | -72M -9.94M | Net income 2023 | 43M 5.93M | EV / Sales 2022 | 1.95 x |
| Net Debt 2022 | 280M 38.58M | Net Debt 2023 | 430M 59.35M | EV / Sales 2023 | 1.86 x |
| P/E ratio 2022 |
-49.6
x | P/E ratio 2023 |
79.2
x | Employees | 2,353 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 69.53% |
More Fundamentals
* Assessed data
More news
| 1 day | -0.79% | ||
| 1 week | +4.59% | ||
| Current month | -5.11% | ||
| 1 month | -4.02% | ||
| 3 months | -9.89% | ||
| 6 months | -13.17% | ||
| Current year | -18.27% |
1 week
4.73
5.14
1 month
4.595.75
Current year
3.756.33
1 year
3.758.08
3 years
3.7510.38
5 years
3.7510.38
10 years
3.0517.99
| Managers | Title | Age | Since |
|---|---|---|---|
Jing Liang Li
CEO | Chief Executive Officer | 55 | 07-08-30 |
Hai Lin Zhao
DFI | Director of Finance/CFO | 49 | - |
Jian Chao Luo
BRD | Director/Board Member | 51 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Jing Liang Li
CEO | Chief Executive Officer | 55 | 07-08-30 |
Jian Chao Luo
BRD | Director/Board Member | 51 | - |
Xiao Hua Yin
BRD | Director/Board Member | 71 | 19-09-08 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 5.01 | -0.79% | 23,475,440 |
| 24-04-25 | 5.05 | +2.02% | 13,668,360 |
| 24-04-24 | 4.95 | -2.17% | 17,942,440 |
| 24-04-23 | 5.06 | +2.85% | 16,765,270 |
| 24-04-22 | 4.92 | +2.71% | 17,841,890 |
End-of-day quote Shanghai S.E., April 25, 2024
More quotes
HENANTALOPHPHARMACEUTICALSTOCKCO., LTD is a China-based company principally engaged in the research and development, manufacture and sales of pharmaceuticals. The Company provides oral solutions, transfusion and tablets, which are applied in the treatment of cold, diabetes and virus infection. The Company's main products include Shuanghuanglian oral liquid products, double gold agents, Haberffine tablets and compound Yimu oral solutions, among others. The Company distributes its products mainly within domestic market.
Sector
Pharmaceuticals
Calendar
2024-08-25
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -18.27% | 387M | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- 600222 Stock
